CDE Catalog

***Please contact the NINDS CDE Team (NINDSCDE@emmes.com) if you encounter any search difficulties.***

The CDE Catalog is a directory of the available NINDS CDEs. Users can search the Catalog to isolate a subset of the CDEs (e.g., all stroke-specific CDEs, etc.), and to view and download details about the CDEs.

Select any filter below to search the CDE Catalog.

For best results, clear form between searches. In addition, when specifying NeuroRehab, Sport-Related Concussion (SRC) or Traumatic Brain Injury (TBI) as the Disease, please select a Subdisease as well.

NeuroRehab Comprehensive includes all NeuroRehab CDE recommendations. NeuroRehab General includes all NeuroRehab CDE recommendations that are not disease specific. All other NeuroRehab Subdiseases include recommendations specific to existing NINDS CDE project disorders.

Choose your Time Frame for your SRC study (Acute (time of injury until 72 hours), Subacute (after 72 hours to 3 months), and Persistent/Chronic (3 months and greater post-concussion) or Comprehensive if your study falls across the study time frames.

Choose your type of TBI study (Acute Hospitalized, Concussion/Mild TBI, Moderate/Severe TBI: Rehabilitation, or Epidemiology) or Comprehensive if your study falls outside of the study types or incorporates aspects of more than one type of study.

Search Form

Displaying 76 - 100 of 409
Operations
Selected 25 rows in this page.  
The search results below can be downloaded by clicking the checkboxes on the far left side of the table. Select the header checkbox to select all CDEs listed on the first page. Then choose CDE Detailed Report from the Choose an operation dropdown menu.
CDE ID CDE Name Definition Classification CRF Name Copyrighted or trademarked Disease Name Subdisease Name
C02499 Imaging pulse sequence type

Type of imaging pulse sequence used

Supplemental Magnetic Resonance (MR) Localization Imaging Huntington's Disease Huntington's Disease
C15056 Brain atrophy substantia nigra pars reticulata neuronal loss severity result

Quantitative result of the severity of neuronal loss in the pars reticulata

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C14956 Huntingtons Disease motor symptom first appeared informant type

The type of initial motor symptoms of Huntington disease (HD) described by the informant

Supplemental Medical History of Huntington's Disease Huntington's Disease Huntington's Disease
C11136 Country origin paternal name

Father's country or countries of origin

Supplemental Demographics Huntington's Disease Huntington's Disease
C53898 Stroop Color and Word Test (SCW) - Word residual score

Score (Residual) of the word test, as part of the Stroop Color and Word Test (SCW)

Supplemental Stroop Test Huntington's Disease Huntington's Disease
C15026 Brain atrophy cerebellum severity result

Quantitative result of the severity of cerebellum atrophy located in the striatum

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C20364 Pittsburgh Sleep Quality Index (PSQI) - Bad dream past month scale

The scale to which the subject had bad dreams during the past month, as part of the Pittsburgh Sleep Quality Index (PSQI)

Supplemental Pittsburgh Sleep Quality Index (PSQI) Huntington's Disease Huntington's Disease
C08099 Pneumonia history indicator

Indicator of whether the participant/subject has ever had pneumonia diagnosed by a physician

Supplemental Infection History Huntington's Disease Huntington's Disease
C08168 Immunohistochemistry stain method name

Name of staining method used for immunohistochemistry

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C10813 Adopted indicator

Indicator of whether the participant was adopted

Supplemental Family History Huntington's Disease Huntington's Disease
C53906 Stroop Color and Word Test (SCW) - Color word residual score

Score (residual) of the color-word test, as part of the Stroop Color and Word Test (SCW)

Supplemental Stroop Test Huntington's Disease Huntington's Disease
C15034 Brain atrophy amygdala neuronal loss severity result

Quantitative result of the severity of neuronal loss in the amygdala

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C20372 Pittsburgh Sleep Quality Index (PSQI) - Sleep quality past month scale

Rating of overall sleep quality past month, as part of the Pittsburgh Sleep Quality Index (PSQI)

Supplemental Pittsburgh Sleep Quality Index (PSQI) Huntington's Disease Huntington's Disease
C00716 Drug or substance illicit use duration

Duration, in years, the participant/subject has used unprescribed, controlled psychoactive drugs or substances

Supplemental Non-prescribed Drug Use Questionnaire Huntington's Disease Huntington's Disease
C08179 Cortical laminar necrosis indicator

Indicator of the presence of selective cortical necrosis of middle and lower cortical lamina most often associated with cerebral hypoperfusion and concentrated in border zones between major cerebral arteries

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C14950 Family history relative order number

A numerical number assigned to each relative, if more than one

Supplemental Family History Huntington's Disease Huntington's Disease
C15042 Brain atrophy fibrillary astrocytosis severity result

Quantitative result of the severity of fibrillary astrocytosis in each location of the caudate nucleus

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C20380 Pittsburgh Sleep Quality Index (PSQI) - Bed partner roommate present scale

The scale that reflects the presence of a bed partner or roommate, as part of the Pittsburgh Sleep Quality Index (PSQI)

Supplemental Pittsburgh Sleep Quality Index (PSQI) Huntington's Disease Huntington's Disease
C17686 Non-prescribed controlled psychoactive drug substance sedative tranquilizer text

The text specifying the drugs within the 'Sedatives/minor tranquilizers/muscle relaxants-benzodiazepines and others: Valium/diazepam, Librium, Halcion, Xanax, Dalmane, Flexeril,' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject

Supplemental Non-prescribed Drug Use Questionnaire Huntington's Disease Huntington's Disease
C14974 Brain atrophy surface status

Status of cerebral atrophy on external surface of the brain upon gross examination

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C08078 Full biological sisters count

Count of full biological sisters the participant/subject has

Supplemental History of Early Exposure to Huntington's Disease Huntington's Disease Huntington's Disease
C15050 Brain atrophy red nucleus neuronal loss severity result

Quantitative result of the severity of neuronal loss in the red nucleus

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C14711 Godin Leisure-Time Exercise Questionnaire - exercise per week scale

The value on a scale describing how often during a typical 7-day week that a participant/subject reports engaging in regular leisure time activity long enough to make the heart beat rapidly

Supplemental Godin Leisure-Time Exercise Questionnaire Huntington's Disease Huntington's Disease
C14941 Diagnosis certainty percentage range type

Option for the range of the clinician's certainty of the medical diagnosis of the disease or disorder

Supplemental Medical History of Huntington's Disease Huntington's Disease Huntington's Disease
C14982 Brain atrophy coronal sections hippocampal formation severity result

Quantitative result of the severity of hippocampal formation atrophy in the coronal sections of the brain

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
Displaying 76 - 100 of 409

The NINDS CDE Team does not post proprietary instruments/scales recommended by the CDE Working Groups on this website. This includes, but is not limited to, copyrighted or trademarked instruments/scales. Information about recommended instruments can be found in the Notice of Copyright (NOC) documents under ‘CRF Module/Guideline’ on each disorder’s data standards page. For any questions regarding these instruments/scales please contact the corresponding owner/author. The NINDS CDE Team is not responsible for the availability or content of these external sites, nor does the NINDS CDE Team endorse, warrant or guarantee the products, services or information described or offered at these other internet sites.